Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF) (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $645000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 16.77% year-over-year to $645000.0, compared with a TTM value of $3.0 million through Dec 2025, down 13.05%, and an annual FY2025 reading of $3.0 million, down 13.57% over the prior year.
  • Depreciation & Amortization (CF) was $645000.0 for Q4 2025 at Arcturus Therapeutics Holdings, down from $800000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $904000.0 in Q1 2024 and bottomed at $200000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $609950.0, with a median of $672500.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 34.85% in 2022, then surged 189.0% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $317000.0 in 2021, then soared by 57.73% to $500000.0 in 2022, then surged by 80.0% to $900000.0 in 2023, then fell by 13.89% to $775000.0 in 2024, then decreased by 16.77% to $645000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ARCT at $645000.0 in Q4 2025, $800000.0 in Q3 2025, and $779000.0 in Q2 2025.